Yubo International Biotech Limited
YBGJ
$0.01
$0.01120.41%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 254.29% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 254.29% | -100.00% | -100.00% |
| Cost of Revenue | -95.00% | -98.02% | -98.03% | -101.94% | -61.34% |
| Gross Profit | 109.76% | 103.87% | 103.92% | 102.20% | -135.44% |
| SG&A Expenses | -37.58% | -37.12% | -19.21% | -14.14% | 7.33% |
| Depreciation & Amortization | -35.00% | -10.58% | -3.06% | -31.37% | -28.32% |
| Other Operating Expenses | 57.01% | -55.41% | -60.40% | -80.86% | -55.71% |
| Total Operating Expenses | -32.82% | -43.77% | -33.26% | -36.46% | -14.28% |
| Operating Income | 33.55% | 44.37% | 33.77% | 35.69% | -11.36% |
| Income Before Tax | 31.43% | 44.08% | 33.75% | 35.70% | -11.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.43% | 44.08% | 33.75% | 35.70% | -11.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -34.76% | -51.72% | -47.34% | 3.14% | 50.00% |
| Net Income | 31.09% | 43.22% | 32.17% | 38.47% | -8.51% |
| EBIT | 33.55% | 44.37% | 33.77% | 35.69% | -11.36% |
| EBITDA | 33.43% | 47.68% | 36.90% | 36.28% | -19.51% |
| EPS Basic | 48.82% | 54.61% | 79.35% | 78.22% | 68.33% |
| Normalized Basic EPS | 48.00% | 53.93% | 79.13% | 78.73% | 68.62% |
| EPS Diluted | 48.82% | 54.61% | 79.35% | 78.22% | 68.33% |
| Normalized Diluted EPS | 48.00% | 53.93% | 79.13% | 78.73% | 68.62% |
| Average Basic Shares Outstanding | 37.60% | 27.04% | 50.30% | 36.58% | 29.03% |
| Average Diluted Shares Outstanding | 37.60% | 27.04% | 50.30% | 36.58% | 29.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |